Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The two main mechanisms for atrial fibrillation (AF) recurrence after cryoablation include Pulmonary vein (PV) reconnection and the presence of non-PV associated arrhythmic focuses. The aim of this study is to reveal the specific biomarkers by antibody microarrays.
One hundred twenty patients with atrial fibrillation will participate in the study.
They will be divided into three groups.
Groups would be formed from patients who previously underwent atrial fibrillation ablations and whose blood samples have been taken and placed in a biobank before interventional treatment. The first step will include proteomic serum profiling using antibody microarrays in ten subjects will be split into 3 groups. The second step will include validation of selected protein biomarkers, in the total cohort (N=120).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| PV associated atrial fibrillation |
| ||
| non-PV associated arrhythmic focuses |
| ||
| Healthy volunteers |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Proteomic analysis by antibody microarrays | Diagnostic Test | Proteomic analysis by antibody microarrays can be used to identify novel biomarkers and to investigate various signaling pathways including protein phosphorylation and protein-protein interactions. Microchips are manufactured as a matrix of a number of immobilized antibodies covalently bound to the glass, membrane, or gel surfaces. Microchips are used for serum proteomic studies in patients with cardiovascular diseases and cancer |
| Measure | Description | Time Frame |
|---|---|---|
| proteins after validation | number of protein which will be specific for non-PV associated arrhythmic focuses group after validation | 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| proteins after screening | number of protein which will be specific for non-PV associated arrhythmic focuses group after screening | 1 year |
Not provided
Inclusion Criteria:
• Patient with paroxysmal/persistent atrial fibrillation who underwent interventional treatment
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients 18-85 years old with s paroxismal or persistant atrial fibrillation and prior interventional treatment
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| National Research Center for Preventive Medicine | Moscow | 101990 | Russia |
Not provided
| ID | Term |
|---|---|
| D001281 | Atrial Fibrillation |
| ID | Term |
|---|---|
| D001145 | Arrhythmias, Cardiac |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D010335 | Pathologic Processes |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| D013568 |
| Pathological Conditions, Signs and Symptoms |